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A main challenge of current research on primary degenerative
dementia is establishing a causal and temporal link between
structural alterations, synaptic and circuit dysfunction, and
cognitive decline. Experimental data support the view that
the observable symptoms of dementia are only the tip of an
iceberg, made up of neuropathological alterations which accu-
mulate over time and lead to loss of synaptic connections and
dysfunction of cortical circuitry [1].
In the clinical setting, current biomarkers are mainly based
on the detection of amyloid deposition and neuronal injury.
Increasing evidence also suggests a role for functional neuro-
imaging and electrophysiological parameters, derived from
functional MRI (fMRI), electroencephalography (EEG), and
transcranial magnetic stimulation, as biomarkers of dysfunc-
tion of neurotransmission and synaptic plasticity in specific
types of primary dementia [2–6].
By considering the two major proteinopathies underlying
Alzheimer’s disease (AD), amyloid beta (Aβ) dysregulation,
and Tau phosphorylation, the initial view of Aβ peptide
accumulation acting as a key upstream event leading to neu-
rodegeneration was put under revision since it has been
acknowledged that these two neuropathological processes
might be initiated independently [7, 8]. Indeed, while amy-
loid accumulation can progress over more than two decades
[9], Aβ markers are not strongly related to cognitive decline
as markers of neurodegeneration [1]. Significantly, in sporadic
AD, impairment of long-term potentiation- (LTP-) like corti-
cal plasticity was found to be associated with a higher cerebro-
spinal fluid total-Tau level and with a faster progression of
cognitive decline [6].
In this effort to establish a link with functional impair-
ment, in AD, attention has long been focused on the central
cholinergic deficit and impairment of synaptic plasticity,
but recent findings also point towards different neurotrans-
mitter systems, prominently towards selective dopaminergic
neuron degeneration leading to hippocampal LTP dysfunc-
tion as a possible upstream phenomenon [10]. A primary
dysfunction of synaptic plasticity, possibly favored by genetic
factors, has also been hypothesized as the leading cause of
molecular and histopathological modifications [11].
A better understanding of such alterations is required for
the development of drugs that target specific pathological
mechanisms. Moreover, the early detection of pathological
changes is crucial for the use of novel disease-modifying
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treatments that need to be administered early in the disease
course [12].
The present Special Issue collects nine articles that con-
tribute to the investigation of cortical circuit and synaptic
dysfunctions related to molecular alterations.
Within the debate on the relationship between Aβ and
Tau pathology, S. Mondragón-Rodríguez et al. review evi-
dence supporting an alternative hypothesis on the role of
Tau phosphorylation as a possible neuroprotective rather
than neurodegenerative mechanism, acting by preventing
synaptic overexcitation during the early stages of AD devel-
opment. In this article, the authors propose that phosphory-
lation of Tau’s microtubule domain is a fundamental part of
the regulatory mechanisms controlling the activity of NMDA
glutamate receptors and synaptic coupling. The presented
hypothesis has important implications for current therapeu-
tic approaches aimed at reducing Tau and phosphorylated
Tau (pTau) levels. Further knowledge on the link between
Aβ and Tau/pTau at the synapse is needed to support the
hypothetic non-pathological role of pTau.
M. A. Aguiar-Furucho and F. J. R. Peláez simulated the
effects of brain aging, so as to reproduce early AD stages, on
a computational model of cortical circuits (of somatosensory,
visual, and auditory cortices) involved in the first level of
processing of sensory afferent inputs. The model, which has
learning capabilities, includes cholinergic excitatory projec-
tions to thalamo-cortical neurons and inhibitory GABAergic
interneurons. Within this model, the authors show that, in
the presence of impaired GABA-A signaling, which has been
described in AD pathophysiology, the reduction of afferent
inputs determines a dysregulation of neuronal excitability that
may facilitate a state of hypermetabolism. While the above
model is focused on function rather than on a specific biolog-
ical substrate, it provides a hypothesis that sensory/cognitive
stimulus reduction might not only facilitate dementia by
weakening cognitive reserve but also represent a direct path-
ophysiological mechanism of neurodegeneration.
J. Li et al. provide an overview of the GABAergic circuitry,
and they highlight the mechanisms through which hippocam-
pal GABAergic impairmentmay cause cognitive deficits under
an ischemic environment, particularly at chronic ischemic
stages. They review evidence of ischemia-induced changes
of the GABAergic system, which has a significant role in pro-
moting neural development and formation of local neural
circuits, including GABA interneurons, extracellular GABA
neurotransmitters, and GABA receptors. Moreover, to bring
new insights and strategies to solving this kind of emerging
cognitive deficits, they also describe exogenous cell transplan-
tation technology, which is effectively supposed to improve
cognition by modulating the GABAergic system.
As far as the Aβ is concerned, C. Gauthier-Umaña et al.
investigated alterations of synaptic activity and plasticity in
an animal model of early Aβ pathology. Results show that
soluble Aβ microinjection in the commissural CA3-to-CA1
circuit increased synaptic variability, impaired long-term
plasticity, increased gamma and high-frequency oscillations
(121-250Hz), and induced a significant γ amplitude-
modulating θ phase shift in anaesthetized Wistar rats. Based
on these results, the authors propose the observed abnor-
mality in θ-to-γ phase-amplitude coupling as a putative bio-
marker of Aβ-induced synaptic dysfunction in the early
stages of AD development.
L. Jorge et al. correlated Aβ pathology and structural
changes between the retinal and primary visual cortex thick-
nesses in a population of AD patients, by means of integrated
imaging techniques. Combining optical coherence tomogra-
phy, magnetic resonance, and positron emission tomography
imaging, the authors measured retinal and primary visual
cortex thicknesses, Aβ retention, and neuroinflammation.
They report that the primary visual cortex showed increased
amyloid-binding potential, in the absence of neuroinflamma-
tion, with a positive association between the synapse-rich
inner plexiform layers of the retina and the primary visual
cortex. This retino-cortical interplay might thus reflect
changes in synaptic function resulting from Aβ deposition in
AD, even when neuronal loss is still not evident.
Interestingly, to therapeutic prospects based on counter-
acting mechanisms of Aβ-related synaptic damage, C. Sheng
et al. present a study aimed at clarifying the molecular basis
of the effects of an empirically used traditional Chinese
medicine compound. They characterized the composition
of Bushen-Tiansui Formula (BTF), generated a chromato-
graphic fingerprint profile, and evaluated the effects of BTF
on cognition and memory functions in a rat model of AD.
The oral administration of BTF reversed the cognitive defects
by reversing the Aβ1–42 fibril-induced reduction of synaptic
marker expression and by promoting the expression of
Brain-Derived Neurotrophic Factors and the activation of
the TrkB/Akt/CREB signaling pathway. This approach
points to the importance of accurately defining the potential
biological targets of any newly proposed treatment strategy.
Relevant to the early diagnosis of AD, H. Liu et al. explore
the possibility of improving the sensitivity of fMRI measures
of cortical connectivity that can be used to predict progres-
sion from Mild Cognitive Impairment (MCI) to AD. They
used the L1-norm linear regression model to test the small-
world attributes of the brain networks of three groups of
subjects composed, respectively, by 33 MCI, 24AD, and 27
healthy controls. They found that the L1-norm was more
sensitive to detect slight small-world network changes in
the early stages of AD with respect to the traditional Pearson
correlation analysis.
Y. Li et al. investigated the relationship between Urinary
Alzheimer-Associated Neuronal Thread Protein (AD7c-
NTP), a marker of neuronal degeneration, and Apolipopro-
tein Epsilon (ApoE) 4 allele in the cognitively normal pop-
ulation. AD7c-NTP has been shown to be increased in
patients with MCI and AD, colocalizing with neurofibrillary
tangles and dystrophic neurites. In this study, while no
significant differences in urinary AD7c-NTP levels were
observed between patients with subjective cognitive decline
and healthy controls, AD7c-NTP levels were significantly
higher in subjects with ApoE3/4 and 4/4, indicating that
also in subjective cognitive decline ApoE4 may modify
AD7c-NTP levels, which are related to Tau and Aβ deposi-
tion. These findings are extremely relevant for the study of
subjective cognitive decline, a stage in which patients report
self-experienced persistent decline in cognitive capacity in
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comparison with a previously normal status, potentially con-
cealing a prodromal state of AD, and that will probably
become a target of disease-modifying treatments.
Finally, the advancements in next-generation sequenc-
ing (NGS) techniques have allowed for rapid, efficient,
and cost-time-effective genetic variant detection. In their
article, G. Lanza et al. performed a neurogenetic study
through an ad hoc NGS-based custom sequencing gene panel
to screen 16 genes in different types of degenerative cognitive
disorders. Notwithstanding the preliminary value of the
study, some rare genetic variants with a probable disease
association were detected, thus suggesting translational
perspectives in the diagnosis and management of a wide
range of neurodegenerative disorders.
Taken together, findings of the studies in this collection
point to the importance of shedding light on the molecular
bases and the pathophysiological mechanisms leading to
dementia, as this might improve the early diagnostic and
prognostic accuracy and therapeutic options.
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